RAPP · NASDAQ
Rapport Therapeutics (RAPP) Stock Price & Fundamentals
Rapport Therapeutics (RAPP) closed at $559.62 on Oct 9, 2026, down 0.83% from the previous close of $564.33.
Share price, past year
1Y +1.80%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $559.62 |
| Sep 30, 2026 | $559.64 |
| Aug 31, 2026 | $556.54 |
| Jul 31, 2026 | $564.67 |
| Jun 30, 2026 | $564.74 |
| May 29, 2026 | $585.56 |
| Apr 30, 2026 | $563.06 |
| Mar 31, 2026 | $533.60 |
| Feb 27, 2026 | $538.17 |
| Jan 30, 2026 | $571.28 |
| Dec 31, 2025 | $570.19 |
| Nov 28, 2025 | $527.23 |
| Oct 31, 2025 | $563.59 |
Key statistics
- Market cap
- $26.84B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.04
- Revenue (TTM)
- —
- Net income (TTM)
- −$137.16M
- Shares outstanding
- 48M
- Dividend yield
- —
- 52-week range
- $521.10 – $593.24
Rapport Therapeutics's market cap is $26.84B, based on a share price of $559.62 and 48M shares outstanding as of Jun 30, 2026.
Financials
Rapport Therapeutics reported a net loss of $111.48M in fiscal 2025.
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$56.62M | −$1.19 |
| Q1 FY2026ended Mar 31, 2026 | $20.00M | −$19.86M | −$0.42 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$26.73M | −$0.75 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$24.06M | −$0.68 |
Company profile
- Name
- Rapport Therapeutics, Inc.
- Ticker
- RAPP
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 99 High Street, Suite 2100, Boston, MA 02110
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0002012593
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 10, 2026
- May 7, 2026
- May 7, 2026
- Apr 21, 2026
- Mar 10, 2026
- Mar 10, 2026
Frequently asked questions
What is Rapport Therapeutics's stock price?
Rapport Therapeutics (RAPP) closed at $559.62 on Oct 9, 2026, down 0.83% from the previous close of $564.33.
What is Rapport Therapeutics's market cap?
Rapport Therapeutics's market cap is $26.84B, based on a share price of $559.62 and 48M shares outstanding as of Jun 30, 2026.
Does Rapport Therapeutics pay a dividend?
Rapport Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Rapport Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures